5005 MCCONNELL AVE, LOS ANGELES, CA
Phase 2a Trial of Bacteriophage Cocktail (AP-SA02) vs. Placebo in Staphylococcus aureus Bacteremia
Corporate Presentation Deborah Birx, M.D. Chief Executive Officer 27 th Annual Global Investment Conference September 10, 2025
Announces Second Quarter 2025 Results and Provides Corporate Update
Shareholder votes
Investor Presentation
Announces First Quarter 2025 Results and Provides Corporate Update
Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Initial Statement of Beneficial Ownership
Submission Upload
Correspondence